<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02104440</url>
  </required_header>
  <id_info>
    <org_study_id>CSM/CIT</org_study_id>
    <secondary_id>2013-000534-35</secondary_id>
    <nct_id>NCT02104440</nct_id>
  </id_info>
  <brief_title>Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Red de Terapia Celular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Navarrra Hospital (Clinica Universitaria)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospitales Universitarios Virgen del Rocío</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish National Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Red de Terapia Celular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of the sequential infusion&#xD;
      of allogeneic mesenchymal stem cells (MSC), expanded &quot;in vitro&quot; with platelet lysate without&#xD;
      addition of animal products in the treatment of patients undergoing allo-HSCT who developed&#xD;
      one or more cytopenias.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse effects at the time of infusion and infections after infusion of MSC</measure>
    <time_frame>During the period of infusion of the cells into the patient (an average of one hour)</time_frame>
    <description>All the adverse effects that may arise and possible toxicities (WHO grade) after infusion of the cells were collected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mesenchymal cell efficiency in recovering cytopenia</measure>
    <time_frame>Monitoring will be from the last infusion of MSCs to the patient until 90 days after the last administration</time_frame>
    <description>The efficiency is measured by the recovery of cytopenia after administration of MSC (depending on the original cytopenia) and may be of two types:&#xD;
Complete response:&#xD;
Hb&gt; 10 g / dL&#xD;
Neutrophils&gt; 1500 Million / L&#xD;
Platelets&gt; 100.000 Million / L&#xD;
Maintained at least 7 days&#xD;
Partial response:&#xD;
Hb&gt; 8 and &lt;10 g / dL&#xD;
Neutrophils&gt; 1000 and &lt;1500 Million / L&#xD;
Platelets&gt; 50000 and &lt;100.000 Million / L&#xD;
Maintained at least 7 days</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Cytopenia</condition>
  <arm_group>
    <arm_group_label>Patients with cytopenia after allo-HSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with cytopenia after allo-HSCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sequential infusion of allogeneic mesenchymal stem cells expanded &quot;in vitro&quot;</intervention_name>
    <arm_group_label>Patients with cytopenia after allo-HSCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with hematologic malignancies who have been subjected to allo-HSCT and that&#xD;
             are diagnosed with one or more peripheral cytopenias with complete chimerism in bone&#xD;
             marrow (determined by molecular-STR-studies). They may include:&#xD;
&#xD;
               1. Patients who have received as a source of cells MO or SP&#xD;
&#xD;
               2. Patients who have received cells from a related donor or unrelated HLA-matched&#xD;
&#xD;
               3. Patients transplanted with myeloablative or non-myeloablative conditioning&#xD;
&#xD;
          -  Adequate cardiac function assessed from a clinical point of view by the researcher,&#xD;
             with no history of ischemic heart disease (angina or myocardial infarction) in the&#xD;
             previous 6 months.&#xD;
&#xD;
          -  Adequate pulmonary function assessed clinically without evidence of severe obstructive&#xD;
             or restrictive lung disease.&#xD;
&#xD;
          -  Patients between 18 and 70 years&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients whose haemopathy has not been controlled by the transplantation or is in&#xD;
             progress at the time of treatment.&#xD;
&#xD;
          -  Patients who do not have complete chimerism in bone marrow (performed within 28 days&#xD;
             prior to baseline by molecular study -STR-).&#xD;
&#xD;
          -  Patients with thrombotic microangiopathy.&#xD;
&#xD;
          -  Patients with post-transplant cytopenias with toxic origin in relation to antiviral&#xD;
             treatment (eg ganciclovir, valganciclovir) without concomitant graft against host&#xD;
             disease.&#xD;
&#xD;
          -  Patients with bacterial, viral or fungal infection that is not being controlled with&#xD;
             proper treatment.&#xD;
&#xD;
          -  Patients with a history of ischemic heart disease (angina or myocardial infarction) in&#xD;
             the previous 6 months, and those considered by the investigator does not have adequate&#xD;
             cardiac function, evaluated from a clinical point of view.&#xD;
&#xD;
          -  Patients with poor lung function, evaluated clinically, according to the researcher.&#xD;
&#xD;
          -  Patients who, in the opinion of the investigator, are not on a good position to&#xD;
             tolerate treatment.&#xD;
&#xD;
          -  Patients who do not have the required donor.&#xD;
&#xD;
          -  Women pregnant or at risk of pregnancy by contraceptive measures inadequate.&#xD;
&#xD;
          -  Patients &lt;18 or &gt; 70 years.&#xD;
&#xD;
          -  Patients who did not sign the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fermín Sánchez-Guijo Martín, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinical Hospital of Salamanca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Rifón Roca, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Navarrra Hospital (Clinica Universitaria)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José A Pérez Simón, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Virgen del Rocío</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Clinical Hospital of Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Salamanca/Castilla León</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>January 22, 2014</study_first_submitted>
  <study_first_submitted_qc>April 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Leukopenia</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

